Belgium-based Bone Therapeutics SA, which is developing cell therapies for bone diseases, has appointed Jean Stéphenne as chairman of its board of directors. Mr Stéphenne was previously a member of the corporate executive team at GlaxoSmithKline Plc and chief executive of GSK Biologicals, now GSK Vaccines. He currently serves on the boards of a number of life science companies including TiGenix NV of Belgium and CureVac AG of Germany.
Bone Therapeutics announced the appointment on 20 February 2018.
Copyright 2018 Evernow Publishing Ltd